Management of hypertension in patients with diabetic kidney disease: summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021

Banerjee, D. et al. (2022) Management of hypertension in patients with diabetic kidney disease: summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021. Kidney International Reports, 7(4), pp. 681-687. (doi: 10.1016/j.ekir.2022.01.004) (PMID:35497783) (PMCID:PMC9039464)

[img] Text
269670.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

674kB

Abstract

Diabetic kidney disease (DKD) accounts for >40% cases of chronic kidney disease (CKD) globally. Hypertension is a major risk factor for progression of DKD and the high incidence of cardiovascular disease and mortality in these people. Meticulous management of hypertension is therefore crucial to slow down the progression of DKD and reduce cardiovascular risk. Randomized controlled trial evidence differs in type 1 and type 2 diabetes and in different stages of DKD in terms of target blood pressure (BP). Renin-angiotensin blocking agents reduce progression of DKD and cardiovascular events in both type 1 and type 2 diabetes, albeit differently according to the stage of CKD. There is emerging evidence for the benefit of sodium glucose cotransporter 2, nonsteroidal selective mineralocorticoid antagonists, and endothelin-A receptor antagonists in slowing progression and reducing cardiovascular events in DKD. This UK guideline, developed jointly by diabetologists and nephrologists, has reviewed all available current evidence regarding the management of hypertension in DKD to produce a set of comprehensive individualized recommendations for BP control and the use of antihypertensive agents according to age, type of diabetes, and stage of CKD (https://ukkidney.org/sites/renal.org/files/Management-of-hypertension-and-RAAS-blockade-in-adults-with-DKD.pdf). A succinct summary of the guideline, including an infographic, is presented here.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mark, Professor Patrick
Authors: Banerjee, D., Winocour, P., Chowdhury, T. A., De, P., Wahba, M., Montero, R., Fogarty, D., Frankel, A., Goldet, G., Karalliedde, J., Mark, P. B., Patel, D., Pokrajac, A., Sharif, A., Zac-Varghese, S., Bain, S., and Dasgupta, I.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Kidney International Reports
Publisher:Elsevier
ISSN:2468-0249
ISSN (Online):2468-0249
Published Online:13 January 2022
Copyright Holders:Copyright © 2022 International Society of Nephrology
First Published:First published in Kidney International Reports 7(4): 681-687
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record